Gilead Sciences (GILD) News Today

Gilead Sciences, Inc. (NASDAQ: GILD) has been getting a lift from encouraging clinical news and improving analyst sentiment, even as the stock has faced some recent weakness. The biggest driver appears to be positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis, where the drug showed statistically significant improvement in a key liver marker versus placebo. Investors are also reacting to additional reports of durable efficacy and safety data, which may support broader use of the drug and strengthen Gilead’s liver-disease franchise.

• Positive Sentiment: Gilead reported positive late-stage Livdelzi data in primary biliary cholangitis, reinforcing the drug’s commercial potential and supporting the company’s liver-disease growth story. Article Title
• Positive Sentiment: Additional coverage highlighted long-term efficacy and safety data for Livdelzi, which could help Gilead expand the drug’s reach in PBC. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, a sign that analyst confidence is improving.
• Positive Sentiment: Cencora said it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, helping Gilead’s cell-therapy business maintain access and commercialization momentum. Article Title
• Neutral Sentiment: Gilead remains in the spotlight because investors are closely watching the stock and the company’s broader pipeline, but that attention alone does not change fundamentals. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan, which can still create a modest headwind for sentiment despite being routine. Article Title

Overall, Gilead Sciences (GILD) appears to be moving higher mainly on pipeline optimism around Livdelzi and supportive analyst coverage, while insider selling is a small offset. Recent valuation-focused articles also note the stock’s recent pullback, which may be drawing investor attention as a potentially more attractive entry point.